Needham initiated coverage of Hinge Health (HNGE) with a Buy rating and $47 price target Hinge is the market leader in the virtual musculoskeletal space boasting both a technological and contracting advantage, the analyst tells investors in a research note. The firm expects this to not only enable market share gains against other digital peers, but also legacy in-person physical therapy over time. The musculoskeletal category represents a “massive opportunity” in the U.S. as 40% of Americans have an MSK issue, but only 9% currently receive treatment, creating a $420B economic burden, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health initiated with an Outperform at William Blair
- Hinge Health initiated with an Outperform at Evercore ISI
- Hinge Health: A Compelling Buy with Innovative Digital Solutions and Favorable Valuation
- Hinge Health, Inc.: A Leader in Digital MSK Care with Strong Growth Potential and High ROI
- Hinge Health initiated with a Buy at Truist